Bolt Biotherapeutics vs Kyntra Bio
BOLT and KYNB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BOLT and KYNB compare
Kyntra Bio is the larger company, worth 1.2 times as much as Bolt Biotherapeutics ($14.9M against $12.1M).
Bolt Biotherapeutics grew revenue faster over the last twelve months (12.8% versus −37.1% for Kyntra Bio).
Kyntra Bio keeps more of each dollar of sales as profit, with a net margin of 3968% compared with −611% at Bolt Biotherapeutics.
Bolt Biotherapeutics scores higher on the StockData Score (11 against 5 for Kyntra Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BOLT | KYNB |
|---|---|---|
| Size and price | ||
| Market cap | $12.1M | $14.9M |
| Share price | $6.26 | $3.68 |
| Change, 1 year | 27.2% | −66.5% |
| Change, 5 years | −96.4% | −98.8% |
| Beta (5Y) | 0.63 | 1.26 |
| Employees | 23 | 34 |
| StockData Score | ||
| Total score | 11 (better) | 5 |
| Valuation score | 3 (better) | 2 |
| Growth score | 2 (better) | 0 |
| Performance score | 1 | 2 (better) |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 0.1× |
| P/S | 2.6× (better) | 3.2× |
| P/B | 1.0× | – |
| FCF yield | – | −255% |
| Fair value | $9.05 | – |
| Margin of safety | 30.9% | – |
| Growth | ||
| Revenue growth (TTM) | 12.8% (better) | −37.1% |
| Revenue growth, 5Y average | 102% (better) | −48.4% |
| Profitability | ||
| Gross margin | – | 6.3% |
| Operating margin | −655% (better) | −1090% |
| Net margin | −611% | 3968% (better) |
| FCF margin | – | −824% |
| Return on equity | −112% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −5.4× |
| Current ratio | 2.61 | 2.69 (better) |
| Altman Z-score | −18.27 (better) | −24.47 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Buyback yield | −0.25% | – |
| Shareholder yield | −0.25% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 31.0% | 24.7% |
| Held by insiders | 12.2% | 15.7% |
| Insider net buying, 12 months | $196K (better) | $39.7K |
| Short interest, % of float | 2.8% | 2.8% |
Go deeper
- BOLT stock overview
- BOLT income statement
- BOLT valuation and score
- KYNB stock overview
- KYNB income statement
- KYNB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.